In patients with recurrent unilateral favorable-histology Wilms tumor, the estimated 5-year overall survival rate after relapse is approximately 67% regardless of detection modality.
TL;DR · AI-generated
In patients with favorable-histology WT, elimination of CT scans from surveillance programs is unlikely to compromise survival but would result in substantial reduction in radiation exposure and health care costs.
Author-implied confidence
88%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
95% → 95% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
· openalex W2896066577 · s2 2eb63559
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1380
Surveillance CT detection of Wilms tumor recurrence does not improve 5-year overall survival after relapse compared with chest X-ray and abdominal ultrasound surveillance (65% vs 73%, P=0.20).
0.1385
Among recurrences detected by surveillance imaging, a larger number of tumor foci at relapse and largest focus size greater than 2 cm are independently associated with inferior overall survival in favorable-histology Wilms tumor.
0.1589
Recurrences detected by CT surveillance occur at a shorter median time from diagnosis (0.60 years) compared with those detected by signs/symptoms (0.91 years) or CXR/US (0.86 years) in favorable-histology Wilms tumor.
0.2117
Eliminating CT scans from routine surveillance programs for favorable-histology Wilms tumor is unlikely to compromise patient survival while substantially reducing radiation exposure and healthcare costs.
0.2952
By 2028, 10-year survival data from CheckMate-067 will show a plateau ≥40% in the combination arm.
0.3003
Recent follow-up analyses of CheckMate-067 are confirming the original effect size in real-world data.